Two Survival Wins in NSCLC With Bispecific Seeking Worldwide Status

The bispecific antibody ivonescimab demonstrated a statistically significant improvement in overall survival over single-agent pembrolizumab in PD-L1-positive advanced non-small cell lung cancer in an updated phase 3 analysis. The drug targets both PD-1 and VEGF, combining checkpoint inhibition with anti-angiogenic activity in a single molecule. Based on two separate survival wins, the manufacturer is now pursuing worldwide regulatory submissions to challenge pembrolizumab as the first-line standard of care.